SCHEMBL986573

SCHEMBL986573

CCC=NC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13970112 1.00
SCHEMBL986572 1.00
SCHEMBL22952855 0.75
SCHEMBL7111855 0.75
SCHEMBL7111853 0.75
SCHEMBL987640 0.75 FFAR1 (0.31)
SCHEMBL987638 0.75 FFAR1 (0.31)
SCHEMBL28779510 0.73 ALDH1A1 (0.31)
SCHEMBL18651103 0.73 PPARA (0.31)
SCHEMBL17084275 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112279749-B Synthetic method of 2-methyl-3- (4-tert-pentylphenyl) propanol 镇江卡博医药科技有限公司 2022-06-07 CN disclosed
CN-112279749-A Synthetic method of 2-methyl-3- (4-tert-pentylphenyl) propanol 镇江卡博医药科技有限公司 2021-01-29 CN disclosed
US-8835475-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2014-09-16 US disclosed
US-8501794-B2 Compounds as cannabinoid receptor ligands ABBVIE INC. (US) 2013-08-06 US disclosed
EP-2344463-A2 1,2 -THIAZOL YL DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2011-07-20 EP disclosed
US-20110082116-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2011-04-07 US disclosed
US-7872033-B2 N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100234345-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-09-16 US disclosed
WO-2010054024-A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2010-05-14 WO disclosed
EP-2146973-A2 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS Abbott Laboratories (US) 2010-01-27 EP disclosed
US-20090023789-A1 N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants ABBOTT LABORATORIES (US) 2009-01-22 US disclosed
WO-2008130953-A2 2-IMIN0IS0THIAZ0LE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS ABBOTT LABORATORIES (US) 2008-10-30 WO disclosed
US-20040152903-A1 6-chloro-3-pyridylmethylpropylamine derivatives, preparation process thereof and bactericides KUREHA CORPORATION (JP) 2004-08-05 US disclosed
EP-1375483-A1 6-CHLORO-3-PYRIDYLMETHYLPROPYLAMINE DERIVATIVES, PREPARATION PROCESS THEREOF AND BACTERICIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2004-01-02 EP disclosed
EP-0710646-B1 1,5-Disubstituted 7a-methylperhydroinden-3a-ol derivatives, active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them SIGMA TAU IND FARMACEUTI (IT) 1998-12-16 EP disclosed
US-5705531-A CONGESTIVE HEART FAILURE AND HYPERTENSION TREATMENT SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 1998-01-06 US disclosed
EP-0710646-A1 1,5-disubstituted 7a-methylperhydroinden-3a-ol derivatives, active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 1996-05-08 EP disclosed
US-3979425-A FRAGRANGES, PERFUMES FIRMENICH S.A. (CH) 1976-09-07 US disclosed
US-3963783-A PERFUMES, ARTIFICIAL ESSENTIAL OILS FIRMENICH S.A. (CH) 1976-06-15 US disclosed